News

BI-204 is a human monoclonal antibody that specifically targets oxidised forms of a low-density lipoprotein (LDL) which has been linked to increased inflammatory processes leading to plaque formation

AOBO is a pharmaceutical company engaged in improving health through the manufacture, development and commercialisation of prescription and over-the-counter (OTC) products. AOBO has posted a net income of

The clinical results from Flexible Stenting Solutions’ supplementary study conducted in Germany were presented by principle investigator Dierk Scheinert of University of Leipzig – Heart Center. The primary

Nabi initiated this clinical trial in March 2010 and expects to have final data in early 2012. The first clinical trial was initiated in November 2009 and completed

The Emblem study was designed to evaluate the efficacy and safety of Epratuzumab (in combination with immunosuppressants) in SLE, identify an optimal dose and regimen for further studies,

WuXi PharmaTech has posted a net income of $44.26m for the third quarter 2010, or $0.59 per diluted share, compared to net income of $14.33m, or $0.19 per

Vyteris is the maker of the first active, ready-to-use drug delivery patch (LidoSite) to receive marketing clearance from the US Food and Drug Administration. Vyteris said that the

Immunologix holds the exclusive worldwide license rights to a proprietary technique used to produce fully human antibodies. GenScript claimed that it offers antibody drug services that include antigen

Phytomedics is a healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources. PMI-001 is a novel, oral, disease-modifying, botanical drug for